# Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System

Study · id `cardio:ct-nct05540223` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05540223](<https://clinicaltrials.gov/study/NCT05540223>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05540223

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1861 participants.

## Technical summary

Registry record NCT05540223. Randomized; no masking; primary purpose treatment. Start 2024-05-13 (actual); primary completion 2027-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1861 participants (enrolled count; ClinicalTrials.gov record NCT05540223, source copy `cardio:ctgov-nct05540223-2026-07-07`, retrieved 2026-10-26)
- Started: 2024-05-13 (actual) (ClinicalTrials.gov record NCT05540223, source copy `cardio:ctgov-nct05540223-2026-07-07`, retrieved 2026-10-26)
- Primary completion: 2027-02 (anticipated) (ClinicalTrials.gov record NCT05540223, source copy `cardio:ctgov-nct05540223-2026-07-07`, retrieved 2026-10-26)
- Completion: 2032-02 (anticipated) (ClinicalTrials.gov record NCT05540223, source copy `cardio:ctgov-nct05540223-2026-07-07`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT05540223, source copy `cardio:ctgov-nct05540223-2026-07-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05540223-2026-07-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System
- Acronym: BIOMAG-II
- Condition: Coronary Artery Disease
- Condition: Atherosclerosis, Coronary
- Condition: Myocardial Ischemia
- Condition: Ischemic Heart Disease
- Condition: Acute Coronary Syndrome
- Condition: Angina Pectoris
- Intervention (Device): Freesolve RMS
- Intervention (Device): Xience DES
- Lead sponsor: Biotronik AG
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Biotronik AG (`cardio:org-biotronik-ag`)

## Provenance

Content hash: 1ab827d118c4829ab5176e6bf8ca707479b954f1d25d4e33a7150f42161c3a7c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
